Welcome to our dedicated page for Forte Biosciences SEC filings (Ticker: FBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Forte Biosciences, Inc. (NASDAQ: FBRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Forte is a clinical-stage biopharmaceutical company focused on FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related diseases, and its filings document key financial, clinical and corporate developments around this program.
Through forms such as 10-Q and 8-K, Forte reports its quarterly financial results, including research and development expenses tied to FB102 clinical and manufacturing activities, general and administrative costs, and net loss figures. Current reports on Form 8-K also disclose material events such as positive phase 1b data in celiac disease, the initiation and status of clinical trials, and the filing of related investor presentations.
Forte’s filings further describe capital markets transactions, including an underwriting agreement for a public offering of common stock and pre-funded warrants. In these documents, the company outlines the number of shares and pre-funded warrants offered, expected gross and net proceeds, use of proceeds for working capital and FB102 development, and the terms and limitations associated with the pre-funded warrants.
On Stock Titan, these SEC filings are supplemented with AI-powered summaries that highlight the main points from lengthy documents, helping readers quickly understand the implications of Forte’s 10-Qs, 8-Ks and other filings. Real-time updates from the EDGAR system, along with organized access to financial reports and material event disclosures, allow investors and researchers to review Forte Biosciences’ regulatory history and ongoing obligations as a Nasdaq-listed, clinical-stage biopharmaceutical company.
Forte Biosciences reported that its Chief Financial Officer, Riley Antony A, received new equity awards effective January 12, 2026. The awards include a stock option covering 90,000 shares of common stock with an exercise price of $29.66 per share and an expiration date of January 12, 2036, and a grant of 60,000 restricted stock units (RSUs).
The option vests monthly, with one forty-eighth of the total option shares vesting each month starting from a vesting commencement date of January 1, 2026, so that the option is fully vested after four years. The RSUs vest annually, with one fourth of the total RSUs vesting on each anniversary of the same January 1, 2026 vesting commencement date, resulting in full vesting over four years, assuming the CFO continues to serve as a Service Provider under the company’s 2021 Equity Incentive Plan.
Forte Biosciences, Inc. reported new equity awards to a senior executive. A Form 4 filing shows that on January 12, 2026, CEO, Secretary and Chair Paul A. Wagner received a stock option covering 270,000 shares of Forte Biosciences common stock with an exercise price of $29.66 per share. According to the vesting terms, one forty-eighth of the option vests each month after a vesting commencement date of January 1, 2026, so the option becomes fully vested after four years, as long as he continues as a service provider.
The filing also reports a grant of 180,000 restricted stock units, each representing a contingent right to receive one share of Forte Biosciences common stock. These RSUs vest in four equal annual installments on each anniversary of the same January 1, 2026 vesting commencement date, again conditioned on continued service. Following these grants, Wagner beneficially owns 270,000 stock options and 180,000 RSUs directly.
Forte Biosciences, Inc. received an updated ownership report from investor Steven Michael Oliveira and Nemean Asset Management, LLC. Together they report beneficial ownership of 300,100 shares of Forte Biosciences common stock, representing 2.4% of the outstanding class as of the event date of 01/08/2026. Voting and disposition power over these shares is reported as shared rather than sole.
The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Forte Biosciences, and that they are not participating in any control-related transaction.
Forte Biosciences (FBRX) filed its Q3 2025 10‑Q, reporting continued investment in FB102 and a larger cash position. The company recorded a Q3 net loss of $17.7 million, driven by research and development expenses of $15.2 million and general and administrative costs of $3.2 million.
Cash and cash equivalents were $93.4 million as of September 30, 2025, supported by a June public offering that raised gross proceeds of $75.0 million and an additional $1.8 million from an underwriter option in July. Net cash used in operating activities for the nine months was $34.4 million.
FB102 advanced clinically: a Phase 2 celiac study began in July 2025, and the FDA approved an IND in November 2025 for a U.S. arm. Earlier, the celiac Phase 1b showed statistically significant histology and symptom improvements. Vitiligo and alopecia areata Phase 1b studies are ongoing. Shares outstanding were 12,526,935 as of November 7, 2025; 5,304,511 pre‑funded warrants remained outstanding as of quarter‑end.
Forte Biosciences, Inc. filed a current report to note that it issued a press release with its financial results for the quarter ended September 30, 2025. The press release, dated November 14, 2025, is included as Exhibit 99.1 to the report.
Federated Hermes, Inc. and affiliated reporting persons disclosed beneficial ownership of 1,635,380 shares of Forte Biosciences, Inc. common stock, representing 13.15% of the class as of the event date. The filing lists Federated Hermes, Inc. (a Pennsylvania entity) and the Voting Shares Irrevocable Trust as holders with sole voting and dispositive power over the 1,635,380 shares, while three individuals — Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue — are reported with shared voting and dispositive power over the same aggregate amount.
The statement affirms the securities were acquired and are held in the ordinary course of business and were not acquired with the purpose of changing or influencing control of the issuer. The filing includes exhibits for classification of reporting persons, a joint filing agreement, and a power of attorney.
Forte Biosciences insider Riley Antony A, identified as the company's Chief Financial Officer, reported transactions dated 10/01/2025. The filing shows 375 restricted stock units (RSUs) were recorded as acquired/awarded with a $0 per-share conversion value, representing a contingent right to receive one share each. The report also discloses a separate sale/disposition of 134 common shares at $14.52 per share. Following the transactions, the filing lists 31,974 and 31,840 shares beneficially owned in the non-derivative lines and 1,875 shares underlying RSUs in the derivative section. The RSU award vests quarterly at one-sixteenth per quarter, subject to continued service, per the 2021 Equity Incentive Plan.
Paul A. Wagner, CEO, Secretary and Chair of Forte Biosciences, Inc. (FBRX), reported an award of 1,250 restricted stock units (RSUs) on 10/01/2025. Each RSU converts into one share of common stock at $0. The RSUs vest in 16 quarterly installments (one-sixteenth each) beginning on or immediately after February 1, 2023, subject to continued service under the 2021 Equity Incentive Plan. The report also shows a separate sale of 98 shares on 10/01/2025 at $14.52, leaving total beneficial ownership of 82,092 shares after the transactions.
Forte Biosciences filed a Form S-8 to register securities for an employee benefit plan and incorporates by reference prior S-8 registration statements and recent SEC reports, including its annual report for the fiscal year ended December 31, 2024 and quarterly reports for March 31, 2025 and June 30, 2025. The filing lists exhibits such as the specimen stock certificate, the 2020 Inducement Equity Incentive Plan and related award agreement forms, legal and audit consents, and a filing fee table.
Federated Hermes, Inc. and related parties reported ownership of 1,478,647 shares of Forte Biosciences, Inc. (common stock), representing 11.89% of the class. The Schedule 13G/A identifies Federated Hermes, Inc. (Pennsylvania) and the Voting Shares Irrevocable Trust as beneficial owners with sole voting and dispositive power over those shares. Individual reporting persons Thomas R. Donahue, Ann C. Donahue and J. Christopher Donahue are listed with shared voting and dispositive power over the same aggregate amount. The filing includes issuer address details and certifications that the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing control. Signatures on the filing are dated 09/05/2025 and the event date requiring the filing is noted as 08/31/2025.
Federated Hermes, Inc. and related parties reported ownership of 1,478,647 shares of Forte Biosciences, Inc. (common stock), representing 11.89% of the class. The Schedule 13G/A identifies Federated Hermes, Inc. (Pennsylvania) and the Voting Shares Irrevocable Trust as beneficial owners with sole voting and dispositive power over those shares. Individual reporting persons Thomas R. Donahue, Ann C. Donahue and J. Christopher Donahue are listed with shared voting and dispositive power over the same aggregate amount. The filing includes issuer address details and certifications that the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing control. Signatures on the filing are dated 09/05/2025 and the event date requiring the filing is noted as 08/31/2025.
Federated Hermes, Inc. and related parties reported ownership of 1,478,647 shares of Forte Biosciences, Inc. (common stock), representing 11.89% of the class. The Schedule 13G/A identifies Federated Hermes, Inc. (Pennsylvania) and the Voting Shares Irrevocable Trust as beneficial owners with sole voting and dispositive power over those shares. Individual reporting persons Thomas R. Donahue, Ann C. Donahue and J. Christopher Donahue are listed with shared voting and dispositive power over the same aggregate amount. The filing includes issuer address details and certifications that the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing control. Signatures on the filing are dated 09/05/2025 and the event date requiring the filing is noted as 08/31/2025.